Obeticholic acid (Ocaliva)

Unknown / undisclosed

Also known as INT-747

DiscontinuedFXR
WithdrawnUS approval

Evidence outlook · regulatory status

US approval withdrawn (FDA, approved 2016-05-27)

The FDA approved this product and later withdrew the approval, so it has no current US approval. The withdrawal took effect on 2025-11-24. FDA withdrew the accelerated approval under 21 CFR 314.150(d): the required postmarketing trial did not verify clinical benefit. Development was discontinued on 2025-11-24, on a safety finding. The trials below are the product's evidence history.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Other / comorbidity
NCT06691412 · Assiut University
2024-11-15 – 2026-03-01 · Hepatitis B Virus, Steatosis
What this study did
NCT06488911 · Intercept Pharmaceuticals
2024-07-01 – 2025-10-21 · Primary Biliary Cholangitis
What this study did
NCT06715319 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
2021-10-09 – 2024-04-29 · PBC
What this study did
NCT05450887 · Nanjing Chia-tai Tianqing Pharmaceutical
2021-09-23 – 2024-04-09 · Primary Biliary Cholangitis
What this study did
NCT04956328 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2021-07-22 – 2023-09-20 · Primary Biliary Cirrhosis
What this study did
NCT02548351 · Intercept Pharmaceuticals
2015-09-22 – 2023-09-15 · Non Alcoholic Steatohepatitis (NASH)
What this study did
NCT01473524 · Intercept Pharmaceuticals
2012-01 – 2018-12-17 · Primary Biliary Cirrhosis
What this study did
Phase 2/3 (1)
Phase 2 (18)
Other / comorbidity
NCT04939051 · National Cancer Institute (NCI)
2024-01-03 – 2027-09-01 · Barrett Esophagus, Esophageal Adenocarcinoma
What this study did
NCT05573204 · Tanta University
2021-09-01 – 2026-12-30 · Non-alcoholic Steatohepatitis
What this study did
NCT05223036 · National Cancer Institute (NCI)
2023-01-19 – 2026-04-17 · Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma, Familial Adenomatous Polyposis
What this study did
NCT04594694 · Intercept Pharmaceuticals
2019-10-02 – 2025-10-14 · Primary Biliary Cholangitis
What this study did
NCT05239468 · Intercept Pharmaceuticals
2022-03-21 – 2025-09-01 · Primary Biliary Cholangitis
What this study did
NCT07104786 · King Edward Medical University
2023-08-24 – 2024-05-23 · Non Alcoholic Fatty Liver Disease
What this study did
NCT05321524 · Intercept Pharmaceuticals
2015-07-01 – 2023-03-09 · Biliary Atresia
What this study did
NCT02430077 · Abhimanyu Garg
2016-06 – 2022-12 · Familial Partial Lipodystrophy
What this study did
NCT02177136 · Intercept Pharmaceuticals
2015-02-09 – 2018-03-22 · Primary Sclerosing Cholangitis (PSC)
What this study did
NCT02633956 · Intercept Pharmaceuticals
2015-12-04 – 2018-03-12 · Nonalcoholic Steatohepatitis
What this study did
NCT02039219 · Naga P. Chalasani
2014-11-03 – 2018-01-29 · Alcoholic Hepatitis
What this study did
NCT00570765 · Intercept Pharmaceuticals
2008-01-17 – 2017-09-25 · Liver Cirrhosis, Biliary
What this study did
NCT01865812 · Intercept Pharmaceuticals
2013-12-03 – 2016-09-12 · Primary Biliary Cirrhosis
What this study did
NCT01625026 · Sahlgrenska University Hospital
2013-09 – 2016-04 · Obesity, Gallstones
What this study did
NCT01265498 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2011-03 – 2014-09 · Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
What this study did
NCT01585025 · Imperial College Healthcare NHS Trust
2012-04 – 2014-02 · Primary Bile Acid Malabsorption, Secondary Bile Acid Malabsorption, Chronic Diarrhoea
What this study did
NCT00550862 · Intercept Pharmaceuticals
2007-10 – 2010-12 · Liver Cirrhosis, Biliary
What this study did
NCT00501592 · Intercept Pharmaceuticals
2007-07 – 2009-04 · Diabetes Mellitus, Type II, Fatty Liver
What this study did
Phase 1 (7)
Other / comorbidity
NCT05133830 · GlaxoSmithKline
2021-11-23 – 2022-05-31 · Pruritus
What this study did
NCT02532335 · Sahlgrenska University Hospital
2015-08 – 2021-06 · Obesity
What this study did
NCT04053023 · GlaxoSmithKline
2019-08-27 – 2019-11-25 · Cholestasis
What this study did
NCT03253276 · University of Aarhus
2016-05-19 – 2018-09-20 · Primary Biliary Cirrhosis
What this study did
NCT01933503 · Intercept Pharmaceuticals
2013-10 – 2013-11 · Healthy
What this study did
NCT01914562 · Intercept Pharmaceuticals
2013-08 – 2013-11 · Healthy
What this study did
NCT01904539 · Intercept Pharmaceuticals
2013-06 – 2013-10 · Hepatic Impairment
What this study did
Phase 4 (2)
Other / comorbidity
NCT02308111 · Intercept Pharmaceuticals
2014-12-26 – 2021-12-23 · Liver Cirrhosis, Biliary
What this study did
NCT03633227 · Intercept Pharmaceuticals
2018-06-22 – 2021-07-09 · Liver Cirrhosis, Biliary
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT05740631 · Universitaire Ziekenhuizen KU Leuven
2022-08-22 – 2023-07-22 · Healthy
What this study did
NCT03836937 · Sir Salimullah Medical College Mitford Hospital
2019-03-05 – 2021-12-31 · Non-Alcoholic Fatty Liver Disease
What this study did
NCT02654236 · Suthat Liangpunsakul
2016-04 – 2019-09 · Alcohol Consumption
What this study did

Competitive landscape

This drug's own stage for Chronic Hepatitis B: Discontinued. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Obeticholic Acid (Ocaliva): this drugDiscontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
Entecavir (Baraclude)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Hepatitis B Immune Globulin (HepaGam B)ApprovedProtein / enzyme therapeuticHBsAgnot yet gradedNo reviewed efficacy summary in this indication
Interferon Alfa-2b (Intron A)ApprovedBiologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
Lamivudine (Epivir-HBV)
ApprovedUS marketing discontinued
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
Peginterferon Alfa-2a (Pegasys)Approved—Type I interferon receptorPartial signalFeatured results are non-efficacy only in this race
Tenofovir Alafenamide (Vemlidy)ApprovedSmall moleculeHBV polymerase (reverse transcriptase)Reliable signalFeatured results are non-efficacy only in this race
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Reliable signal
NCT00116805: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF 66.5 percentage of participants | ADV 10 mg 12.2 percentage of participants
NCT00117676: Percentage of Participants With HBV DNA < 400 Copies/mL and Histological Improvement (2-point Reduction in Knodell Necroinflammatory Score Without Worsening in Knodell Fibrosis Score) at Week 48 (Baseline; Week 48): TDF-TDF — Yes: 70.8 percentage of participants; No: 29.2 percentage of participants | ADV-TDF — Yes: 48.8 percentage of participants; No: 51.2 percentage of participants
Besifovir Dipivoxil (Besivo)Phase 3Small moleculeHBV polymerase (reverse transcriptase)Partial signal
NCT01937806: Primary endpoint at week 48: 80.9% with besifovir vs 84.9% with tenofovir disoproxil fumarate met the virologic response endpoint, showing non-inferiority (Ahn et al., Clin Gastroenterol Hepatol 2019).
Hepatitis B Immune Globulin (I.V.-Hepabig)Phase 3Polyclonal Antibody (human Hepatitis B Immunoglobulin)HBsAgnot yet gradedNo reviewed efficacy summary in this indication
Tenofovir Amibufenamide (Hengmu)Phase 3Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
TQA3605Phase 3—HBV core proteinnot yet gradedNo reviewed efficacy summary in this indication
TVAX-008Phase 3VaccineHepatitis B virus antigens (HBsAg + HBcAg)not yet gradedNo reviewed efficacy summary in this indication
AHB-171Phase 2RNA / oligonucleotideHBV RNAnot yet gradedNo reviewed efficacy summary in this indication
Daplusiran / TomligisiranPhase 2RNA / oligonucleotideHBV RNA (X and S transcripts)not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
HepalatidePhase 2PeptideNTCPnot yet gradedNo reviewed efficacy summary in this indication
Libevitug (HH-003)Phase 2Monoclonal antibodyHBV/HDV large envelope protein (PreS1 domain)not yet gradedNo reviewed efficacy summary in this indication
MetacavirPhase 2Small moleculeHBV reverse transcriptase (nucleoside analog)not yet gradedNo reviewed efficacy summary in this indication
REP 2139-MgPhase 2—HBsAg release (nucleic acid polymer)not yet gradedNo reviewed efficacy summary in this indication
T101Phase 2Biologic (subtype unspecified)HBV core, polymerase and envelope antigensnot yet gradedNo reviewed efficacy summary in this indication
TQA3810Phase 2—TLR8not yet gradedNo reviewed efficacy summary in this indication
CRMA-1001Phase 1/2Gene therapy / editingHBV genome (cccDNA and integrated DNA)not yet gradedNo reviewed efficacy summary in this indication
HepadvaxPhase 1/2VaccineHBsAg (PreS) immunizationnot yet gradedNo reviewed efficacy summary in this indication
Human Serum Albumin / Interferon Alpha2b Fusion ProteinPhase 1/2Biologic (subtype unspecified)Type I interferon receptornot yet gradedNo reviewed efficacy summary in this indication
LW231Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
PA1010Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
TQA3038Phase 1/2——not yet gradedNo reviewed efficacy summary in this indication
ACT201Phase 1RNA / oligonucleotideHBsAgnot yet gradedNo reviewed efficacy summary in this indication
CB06-036Phase 1—TLR8not yet gradedNo reviewed efficacy summary in this indication
DA-2803Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Entecavir (Cavir)
Phase 1(overall)
Small moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
HECN30227Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SA1211Phase 1RNA / oligonucleotideHepatitis B virus RNA (dual-target siRNA)not yet gradedNo reviewed efficacy summary in this indication
TVAX-028Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Adefovir Dipivoxil (Hepsera)DiscontinuedSmall moleculeHBV polymerase (reverse transcriptase)not yet gradedNo reviewed efficacy summary in this indication
PamrevlumabDiscontinuedMonoclonal antibodyCTGFnot yet gradedNo reviewed efficacy summary in this indication
Telbivudine (Tyzeka)Discontinued—HBV polymerase (reverse transcriptase)Partial signal
NCT00076336: Protocol composite at week 52 (HBV DNA <10,000 copies/mL, normal ALT, Child-Turcotte-Pugh score improved or stable), telbivudine vs lamivudine, ITT missing=failure: 56.2% vs 54.0%, non-inferiority not achieved (Chan et al., Aliment Pharmacol Ther 2012). missed

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

24 November 2025WithdrawalFDA withdraws approval of NDA 207999 (Federal Register 2025-20767)
US, FDA · Source ↗